ArticleArthritis & rheumatology (Hoboken, N.J.)2019
Citrullinated Aggrecan Epitopes as Targets of Autoreactive CD4+ T Cells in Patients With Rheumatoid Arthritis.
Article in Arthritis & rheumatology (Hoboken, N.J.), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 63 citations in OpenAlex.
- Aggrecan and polymeric immunoglobulin receptor in extracellular vesicles of patients with seropositive rheumatoid arthritis.Journal of translational autoimmunity · 2026Article
- Specificity, frequency, and phenotype of citrullinated-specific T cells vary with disease activity in rheumatoid arthritis.JCI insight · 2026Article
- Review
- HLA class I-naturally presented synovial tissue peptides are recognized by CD8+ T lymphocytes from rheumatoid arthritis patients.Frontiers in immunology · 2026Article
- Characterization of fibroblast-like synoviocytes from the synovial fluid of patients affected by juvenile idiopathic arthritis.Rheumatology (Oxford, England) · 2025Article
- Antigen presentation of post-translationally modified peptides in major histocompatibility complexes.Immunology and cell biology · 2025Review
- Antigen-specific T-cell frequency and phenotype mirrors disease activity in DRB1*04:04+ rheumatoid arthritis patients.Clinical and experimental immunology · 2025Article
- Synovial Fluid Markers and Extracellular Vesicles in Rheumatoid Arthritis.Medicina (Kaunas, Lithuania) · 2024Review
- Arthritis progressors have a decreased frequency of circulating autoreactive T cells during the at-risk phase of rheumatoid arthritis.RMD open · 2024Article
- The peculiar features, diversity and impact of citrulline-reactive autoantibodies.Nature reviews. Rheumatology · 2024Review
- Autoimmunity: the neoantigen hypothesis.Frontiers in immunology · 2024Article
- Multifaceted immune dysregulation characterizes individuals at-risk for rheumatoid arthritis.Nature communications · 2023Article
- Citrullination modulates antigen processing and presentation by revealing cryptic epitopes in rheumatoid arthritis.Nature communications · 2023Article
- Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database.International journal of molecular sciences · 2023Review
- Cytotoxic CD8Nature communications · 2023Article
- Recognition of mRNA Splice Variant and Secretory Granule Epitopes by CD4+ T Cells in Type 1 Diabetes.Diabetes · 2023Article
- Mechanism-driven strategies for prevention of rheumatoid arthritis.Rheumatology & autoimmunity · 2022Article
- Emerging proteoglycans and proteoglycan-targeted therapies in rheumatoid arthritis.American journal of physiology. Cell physiology · 2022Review
- T peripheral helper cells in autoimmune diseases.Immunological reviews · 2022Review
- Citrullination of glucokinase is linked to autoimmune diabetes.Nature communications · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
Abstract
objectiveRecognition of citrullinated antigens such as vimentin, fibrinogen, and α-enolase is associated with rheumatoid arthritis (RA). Emerging data suggest that the matrix protein aggrecan is also recognized as a citrullinated antigen. This study was undertaken to directly visualize Cit-aggrecan-specific T cells and characterize them in patients with RA.
methodsCitrullinated aggrecan peptides with likely DRB1*04:01 binding motifs were predicted using a previously published scanning algorithm. Peptides with detectable binding were assessed for immunogenicity by HLA tetramer staining, followed by single cell cloning. Selectivity for citrullinated peptide was assessed by tetramer staining and proliferation assays. Ex vivo tetramer staining was then performed to assess frequencies of aggrecan-specific T cells in peripheral blood. Finally, disease association was assessed by comparing T cell frequencies in RA patients and controls and correlating aggrecan-specific T cells with levels of aggrecan-specific antibodies.
resultsWe identified 6 immunogenic peptides, 2 of which were the predominant T cell targets in peripheral blood. These 2 epitopes were citrullinated at HLA binding residues and shared homologous sequences. RA patients had significantly higher frequencies of Cit-aggrecan-specific T cells than healthy subjects. Furthermore, T cell frequencies were significantly correlated with antibodies against citrullinated aggrecan.
conclusionOur findings indicate that T cells that recognize citrullinated aggrecan are present in patients with RA and correlate with antibodies that target this same antigen. Consequently, aggrecan-specific T cells and antibodies are potentially relevant markers that could be used to monitor patients with RA or at-risk subjects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.